Medical Device Regulatory Compliance: EU MDR, IVDR, Approval Timelines & Documentation Requirements

A comprehensive guide for medical device and IVD manufacturers navigating global regulatory frameworks, covering EU MDR and IVDR requirements, documentation, approval timelines, and compliance strategy.

Talk to an Expert

Medical device regulatory compliance is no longer limited to obtaining a single approval.
Manufacturers must manage evolving regulations, technical documentation, quality systems, post market surveillance, labeling, and product changes throughout the entire product lifecycle. As organizations expand into additional markets, compliance has become a strategic business function that directly influences product launches, operational efficiency, and global market access.

What This Guide Covers

  • Medical device regulatory compliance fundamentals
  • EU MDR and IVDR requirements
  • FDA regulatory pathways and QMSR
  • Approval timelines by region
  • Technical documentation requirements
  • Global regulatory considerations
  • Digital tools for compliance management
  • Common compliance challenges and best practices

What Is Medical Device Regulatory Compliance?

Medical device regulatory compliance refers to the continuing process of ensuring that medical devices satisfy all applicable regulatory requirements throughout the product lifecycle including development, manufacturing, commercialization, and post-market monitoring. Regulatory frameworks are designed to protect patient safety, verify device effectiveness, and ensure consistent product quality across healthcare markets. Regulatory compliance is no longer a regional function; it is now a global operational discipline requiring coordinated strategy across multiple regulatory systems.

Manufacturers must comply with requirements set forth by the FDA, the European Commission under EU MDR and IVDR, and international standards organizations such as ISO 13485.  These frameworks define device classification, risk management, clinical evidence, labeling, traceability, quality management systems, and post-market surveillance activities. Recent MedTech Europe regulatory surveys continue to highlight certification timeline challenges, increasing compliance costs, and concerns about the impact of MDR and IVDR implementation on medical device availability and innovation in Europe.

Regulatory compliance extends beyond obtaining initial market authorization. Manufacturers are responsible for maintaining ongoing compliance through complaint handling, CAPA processes, vigilance reporting, post-market surveillance, and periodic updates to technical documentation. Failure to maintain compliance can lead to warning letters, product recalls, import restrictions, or loss of market access.

As requirements become increasingly complex, manufacturers are recognizing compliance as a critical business enabler. Organizations with well-developed regulatory capabilities are better equipped to navigate evolving regulations and maintain uninterrupted access across multiple jurisdictions.

Medical device regulatory compliance extends beyond obtaining market approval. Manufacturers must maintain compliance throughout the product lifecycle through documentation, quality management, post-market surveillance, and continuous regulatory monitoring.

What Does Lifecycle Compliance Mean?

Lifecycle compliance refers to maintaining regulatory compliance from initial product development through commercialization and post market activities. Rather than ending at product approval, manufacturers must continually update technical documentation, monitor device performance, manage product changes, maintain quality systems, and respond to evolving regulatory requirements throughout the life of the device.

Lifecycle compliance is now a fundamental expectation under regulatory frameworks including EU MDR, IVDR, and FDA QMSR, making continuous regulatory oversight an essential part of modern medical device operations.

Why Is Medical Device Regulatory Compliance Becoming More Complex?

Medical device manufacturers face increasing regulatory complexity due to several industry trends:

  • Expanded clinical evidence requirements under EU MDR and IVDR
  • Growing post market surveillance and vigilance obligations
  • Country specific registration and labeling requirements
  • Evolving cybersecurity expectations for connected devices
  • New FDA Quality Management System Regulation (QMSR) requirements
  • Increasing demand for global product launches across multiple markets

As regulatory requirements continue to evolve, organizations are increasingly adopting centralized regulatory processes and digital systems to improve visibility, reduce compliance risk, and support global market expansion.

EU Regulatory Compliance

The EU maintains one of the most rigorous regulatory frameworks for medical devices and IVD products. EU MDR and IVDR significantly expanded regulatory expectations by introducing stricter clinical evidence requirements, enhanced traceability standards, expanded post-market obligations, and increased notified body oversight. Compared with previous regulations, EU MDR places greater emphasis on lifecycle compliance, requiring manufacturers to continually maintain technical documentation, clinical evidence, and post market surveillance activities after commercialization.

EU MDR Overview

The EU MDR replaced the Medical Device Directive (MDD) and introduced stricter requirements for clinical evidence, technical documentation, post-market surveillance, UDI traceability, and notified body oversight. A key difference from MDD is the requirement for continuous lifecycle compliance and greater regulatory transparency. Manufacturers must navigate evolving EUDAMED requirements and longer certification timelines.

EUDAMED

EUDAMED serves as a centralized platform for managing information related to economic operators, medical devices, certificates, clinical investigations, vigilance activities, and market surveillance. It is a central component of the EU regulatory framework, significantly reshaping compliance management.

Key Changes from MDD

    • Expanded clinical evidence requirements
    • Stronger post-market surveillance & PMCF
    • UDI requirements throughout lifecycle
    • EUDAMED transparency platform
    • Increased notified body oversight
    • Continuous lifecycle compliance

EU MDR vs. MDD: Key Differences

Understanding how EU MDR compares to the directive it replaced is essential for manufacturers maintaining EU market access.

Area MDD MDR
Clinical Evidence Limited requirements Expanded clinical and real-world evidence
PMS & PMCF Less prescriptive Continuous PMS and PMCF required
UDI & Traceability Limited Comprehensive UDI requirements
Notified Body Oversight Lower scrutiny Increased audits and technical reviews
Technical Documentation Less detailed Expanded Annex II/III documentation
Device Scope Narrower Includes additional product categories
EUDAMED Not available Centralized regulatory data and transparency
Lifecycle Compliance Premarket focused Continuous lifecycle oversight

The shift from MDD to MDR represents a fundamental change in regulatory philosophy, moving from a declaration-based system to a continuous evidence-based lifecycle model with significantly higher clinical and post-market expectations.

 

IVDR Overview

IVDR replaced the IVDD and established a more risk-based approach for regulating diagnostic devices. Under IVDR, many devices previously self-certified now require notified body review and additional clinical performance evidence. Manufacturers must demonstrate scientific validity, analytical performance, and clinical performance for diagnostic products.

Device Classification

Under EU MDR, devices are classified as Class I, Is, Im, Ir, IIa, IIb, or III based on risk, intended use, invasiveness, and duration of use. Higher-risk devices require more extensive conformity assessments including notified body reviews, QMS audits, and clinical evidence evaluations. Early classification decisions are critical for avoiding delays. Classification decisions directly influence not only submission requirements but also development timelines, clinical strategy, and long-term regulatory maintenance obligations.

Clinical Evidence & Post-Market Surveillance

EU MDR and IVDR significantly increased expectations for clinical evidence and PMS throughout the product lifecycle. Manufacturers must maintain sufficient clinical data using clinical investigations, literature reviews, equivalence assessments, and real-world evidence. Under EU MDR, clinical evidence is no longer viewed as a one-time submission requirement but as an ongoing justification of device safety and performance throughout the product lifecycle. Regulators expect stronger alignment between clinical evidence, risk management, and intended use.

Expanded requirements have increased compliance costs and documentation complexity, particularly for legacy devices. Robust PMS and PMCF programs are essential for monitoring device performance, identifying safety signals, and supporting ongoing regulatory compliance.

Approval Timelines

Regulatory timelines for 510(k), CE Marking, and PMA approvals are increasingly influenced by regulatory capacity constraints, evolving clinical expectations, and documentation complexity rather than fixed statutory review periods. Manufacturers must account for submission preparation, regulatory review, clinical evidence generation, testing activities, and post-submission requests when developing commercialization strategies. Delays in any phase of the regulatory approval process can significantly impact product launches, supply planning, revenue projections, and market competitiveness.

Under EU MDR and IVDR, approval timelines have historically been highly unpredictable due to notified body capacity constraints and inconsistent practices across certification bodies. Average certification times under MDR and IVDR currently run 13–18 months from application acceptance to certificate issuance, not including intake queues at major notified bodies, which can add a further 6–12 months. However, this is changing: Commission Implementing Regulation (EU) 2026/977, adopted May 4–5, 2026, introduces legally binding maximum timelines for each phase of the conformity assessment process, 30 days for application review, 120 days for QMS auditing, and 90 days for product verification. Once in effect, these mandatory timelines are expected to improve predictability for manufacturers, though they apply to each phase independently and do not establish an end-to-end certification guarantee. Additionally, the EU MDR Simplification Package, proposed in December 2025, aims to reduce administrative burden by approximately 30% and address notified body capacity, though adoption is not expected before Q2 2027.

Global Approval Timelines

Region Typical Pathway Approximate Timeline
European Union MDR CE Marking 12–24+ months
United States 510(k) 3–9 months
United States PMA 1–3+ years
United Kingdom UKCA Marking 6–18 months
Canada Medical Device License 4–12 months
Japan PMDA Review 1–2+ years

Actual approval timelines depend on several factors including device classification, submission quality, clinical evidence requirements, notified body availability, regulator workload, and the completeness of technical documentation. Early regulatory planning can significantly reduce delays caused by deficiencies or additional information requests.

Planning Considerations

Leading manufacturers integrate regulatory strategy early in product development to identify applicable pathways, device classifications, evidence requirements, and testing needs before major design decisions are finalized.

Device Classification- Device classification directly influences conformity assessment routes, clinical evidence requirements, and review timelines under EU MDR and IVDR. Misclassification can result in submission rejection, additional testing requirements, or major delays late in the development process.
Clinical Evidence- Early regulatory assessment helps manufacturers identify whether external clinical studies, usability testing, cybersecurity evaluations, or biocompatibility testing will be required prior to submission.
Notified Body Capacity- Early engagement with notified bodies and regulatory authorities has become increasingly important under modern regulatory frameworks.
Submission Quality- Centralized document management systems and structured review workflows help organizations maintain traceability and reduce late-stage submission corrections.
Regulatory Strategy- Successful manufacturers begin regulatory strategy development early in the product lifecycle rather than treating submissions as a final-stage activity.
Cross-Functional Dependencies- Regulatory submissions depend on inputs from engineering, quality assurance, clinical affairs, manufacturing, labeling, and supply chain teams; cross-functional coordination is a vital factor for maintaining realistic regulatory timelines.

Manufacturers operating across multiple global markets must also account for regional differences in regulatory requirements, language expectations, labeling standards, and post-market obligations. Global launch strategies increasingly require staggered submissions, market prioritization, and coordinated documentation management to support simultaneous compliance across jurisdictions.

Strong regulatory planning ultimately improves approval efficiency, audit readiness, and long-term compliance sustainability. Organizations that integrate regulatory strategy early in development are better positioned to reduce rework, avoid submission delays, and maintain consistent market access across global regions.

EU MDR Transitional Timelines

Device Category MDR Transition Deadline
Class III and Class IIb implantable devices December 31, 2027
Class IIb (non-implantable), Class IIa, Class Is, Im, Ir devices December 31, 2028
Legacy devices already placed on the market No fixed sell-off date (removed)

EU IVDR Transitional Timelines

IVDR Risk Class Transition Deadline
Class D IVDs December 31, 2027
Class C IVDs December 31, 2028
Class B and Class A sterile IVDs December 31, 2029

EUDAMED Implementation- Key Dates

Mandatory: May 28, 2026
The first four EUDAMED modules became mandatory: Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance.

November 28, 2026
Legacy devices must be registered in the UDI/Device Registration module.

May 28, 2027
Existing MDR/IVDR certificates must be uploaded by notified bodies.

The remaining EUDAMED modules- Clinical Investigations & Performance Studies and Vigilance/Post-Market Surveillance are still under development. No mandatory date has been announced. For manufacturers managing global portfolios, EUDAMED registration data must now be built into submission planning alongside technical documentation preparation; it is a market access prerequisite, not a post-approval administrative step

Documentation Requirements

Inconsistent or incomplete technical documentation remains one of the leading causes of regulatory delay under EU MDR, often resulting in deficiency requests, extended review cycles, or rejection by notified bodies. Under EU MDR Annex II, manufacturers must maintain comprehensive technical documentation demonstrating conformity with applicable regulatory requirements. The technical file must be kept current throughout the product lifecycle and made available to competent authorities and notified bodies upon request. Modern regulatory documentation is no longer a static submission requirement but a living system of evidence that must remain consistent across design, manufacturing, clinical, and post-market activities.

Technical Documentation

Device descriptions, specifications, design and manufacturing information, verification and validation data, and benefit-risk analyses required under MDR Annex II.

Clinical Evaluation

Demonstrates device safety and performance through clinical investigations, literature reviews, equivalence assessments, and real-world evidence. Must align with intended purpose and risk management. Clinical Evaluation Reports have become one of the most heavily scrutinized components of EU MDR submissions due to increased emphasis on equivalence justification and real-world clinical evidence.

Risk Management

Documented risk management activities throughout the device lifecycle per ISO 14971, including hazard identification, risk evaluation, and risk control measures.

GSPR

Comprehensive evidence of conformity with all applicable General Safety and Performance Requirements under EU MDR Annex I, cross-referenced to harmonized standards.

UDI

Device identification data required for EUDAMED and GUDID registration, including UDI-DI and UDI-PI information, carrier requirements, and submission records.

Post-Market Surveillance

PMS plans, procedures for collecting and evaluating post-market data, and vigilance reporting processes per MDR Annex III, proportionate to device risk class.

Labeling

Instructions for Use (IFU), packaging labels, safety warnings, and UDI information compliant with country-specific formatting, translation, and traceability standards.

Vigilance

Mechanisms for identifying, reporting, and investigating serious incidents and field safety corrective actions. Reporting timelines and thresholds vary across jurisdictions.

Global Regulatory Considerations

While regulatory frameworks differ across regions, global authorities are increasingly aligned around three core principles: risk-based classification, expanded post-market surveillance, and stronger reliance on clinical evidence. Medical device manufacturers operating internationally must navigate a highly fragmented regulatory environment with varying requirements across major global markets. Differences in classification systems, submission pathways, documentation expectations, labeling requirements, and post-market obligations create significant compliance and operational challenges.  Although regulatory requirements differ between regions, manufacturers increasingly benefit from developing a global regulatory strategy that standardizes documentation, quality processes, and regulatory data while allowing for regional market requirements.

Regulatory Authorities by Region

Region Regulatory Authority Common Pathway
United States FDA 510(k), PMA
European Union Notified Bodies CE Marking (MDR/IVDR)
Canada Health Canada Medical Device License (MDL)
United Kingdom MHRA UKCA Marking
Japan PMDA Shonin/Ninsho

Effective global compliance requires proactive planning, centralized regulatory visibility, and strong cross-functional coordination.

Global Compliance Challenges

Device Classification

A device classified as moderate risk in one market may be considered higher risk in another, resulting in additional testing requirements, expanded clinical evidence expectations, or different conformity assessment routes.

Labeling Requirements

Manufacturers must ensure IFU, packaging labels, safety warnings, and UDI information comply with country-specific formatting, translation, and traceability standards across all markets.

Language Requirements

Many markets require native-language labeling, IFU, and regulatory submissions. Translation must be accurate and verified to avoid regulatory findings or shipment delays.

Regional Requirements

Each market maintains distinct regulatory processes that influence evidence requirements, approval timelines, and commercialization strategies, requiring market-specific regulatory expertise.

Post-Market Reporting

While major markets share similar post-market obligations, reporting thresholds, timelines, and documentation, expectations often differ requiring coordinated global monitoring systems.

Global Harmonization

ISO 13485, ISO 14971, IMDRF, and MDSAP initiatives support greater regulatory alignment, helping manufacturers reduce duplication and streamline audits across participating jurisdictions.

Tools & Strategies for Compliance

RIM

Regulatory Information Management platforms centralize regulatory data, submission records, registration information, approval timelines, and market-specific requirements. They improve visibility across global submissions and help track regulatory commitments and renewal deadlines. Platforms such as RegDesk support global regulatory operations through centralized regulatory intelligence, submission management, and market-specific compliance tracking.

PLM

Product Lifecycle Management systems help manufacturers manage product specifications, design controls, engineering changes, and controlled technical documentation. When PLM operates in isolation, organizations may encounter traceability gaps between engineering changes and updated regulatory submissions, labeling, or risk management documentation.

QMS

Quality Management Systems support CAPA management, complaint handling, training records, nonconformance management, and audit tracking. Integrated QMS and PLM systems improve cross-functional visibility and ensure product changes are reflected consistently across regulatory, quality, manufacturing, and clinical documentation.

QMSR Readiness

In the US market, QMSR readiness requires more robust compliance infrastructure than the legacy QSR. Under QMSR and Compliance Program 7382.850, FDA investigators can review internal audits, management reviews, and supplier audit reports during inspections. The inspection approach has also shifted from QSIT subsystem sampling to risk-based evaluation of the entire quality management system, driven by product risks, complaint history, and prior compliance issues. As a result, centralized, traceable, immediately retrievable quality records are now an inspection requirement, making integrated QMS platforms essential for FDA-facing manufacturers.

How AI Is Supporting Medical Device Regulatory Compliance

Modern regulatory organizations increasingly use AI to assist with:

  • monitoring regulatory updates
  • organizing submission documentation
  • identifying affected products after regulatory changes
  • generating submission forms
  • improving document search
  • supporting regulatory intelligence

While AI does not replace regulatory expertise, it helps reduce manual effort and improves visibility across global regulatory operations.

Regulatory Intelligence

Regulatory intelligence tools monitor regulatory updates, guidance changes, harmonized standards revisions, and emerging compliance risks across multiple jurisdictions. Proactive regulatory intelligence helps organizations identify upcoming regulatory changes before they impact submissions, product labeling, or quality system procedures. Solutions like RegDesk integrate regulatory intelligence into their platform and workflows.

Organizations that centralize regulatory information improve visibility, reduce manual effort, and strengthen compliance across global markets.

Common Challenges & Pitfalls

Many compliance challenges are not caused by regulatory complexity alone, but by fragmented internal systems, inconsistent documentation practices, and lack of cross-functional alignment. Medical device regulatory compliance presents significant operational and strategic challenges as global regulations become more complex. Organizations frequently encounter delays, increased costs, and compliance risks when regulatory activities are not integrated effectively across product development, quality systems, clinical operations, and post-market processes.

Incomplete Documentation

Regulatory authorities increasingly expect comprehensive, traceable submission packages. Missing records, unsupported claims, inconsistent document versions, or gaps between risk management and clinical documentation often result in prolonged review cycles.

Changing Regulations

Manufacturers must continuously monitor updates to MDR, IVDR, MDCG guidance, cybersecurity requirements, and country-specific regulations. Failure to implement new expectations in a timely manner may lead to submission delays or disruptions to market access.

Cybersecurity Compliance

Regulators increasingly expect secure software development practices, vulnerability management programs, cybersecurity risk assessments, and ongoing post-market monitoring to address emerging threats throughout the product lifecycle.

Clinical Evidence Shortfalls

Many organizations underestimate the clinical justification required for legacy devices transitioning from MDD and IVDD. Equivalence claims previously accepted may no longer satisfy current scrutiny, forcing additional clinical studies or supplemental performance data.

Cross-Functional Coordination

When communication between departments is inconsistent, organizations encounter issues such as outdated specifications, conflicting documentation, delayed testing, or incomplete change management records, often emerging late in the submission process.

Post-Market Surveillance Demands

Manufacturers must continuously monitor complaint trends, adverse events, CAPA effectiveness, and device performance. Failure to identify safety signals or maintain vigilance reporting can result in warning letters, recalls, or enforcement actions.

Building a Strong Regulatory Compliance Strategy

Medical device regulatory compliance has become increasingly complex as global regulatory authorities continue to strengthen expectations related to safety, clinical evidence, documentation, traceability, and post-market surveillance. Successful compliance now depends on more than obtaining initial regulatory approval.

Manufacturers must continuously manage evolving regulatory requirements, global submission coordination, audit readiness, CAPA activities, labeling updates, and post-market obligations across multiple jurisdictions. Delays caused by incomplete documentation, inconsistent data, or poor cross-functional coordination can significantly impact commercialization timelines and business performance.

Modern compliance strategies rely on collaboration between regulatory affairs, quality assurance, clinical, engineering, manufacturing, and supply chain teams. Digital tools such as RIM, PLM, and QMS platforms support compliance efficiency by improving traceability, workflow control, and global visibility. Platforms such as RegDesk support manufacturers through centralized regulatory intelligence, workflow management, and scalable global compliance operations.

Strong regulatory compliance practices support not only regulatory approvals but also patient safety, product quality, organizational credibility, and sustainable global market access. Successful organizations view regulatory compliance as a continuous operational capability rather than a single submission milestone, integrating regulatory planning throughout product development and commercialization. Manufacturers that invest in scalable compliance processes are better equipped to navigate evolving requirements. As regulatory systems become increasingly interconnected globally, successful compliance strategies will depend less on individual market expertise and more on integrated, lifecycle-based regulatory intelligence.

Expanded requirements have increased compliance costs and documentation complexity, particularly for legacy devices. Robust PMS and PMCF programs are essential for monitoring device performance, identifying safety signals, and supporting ongoing regulatory compliance.

Simplify Global Medical Device Compliance

See how RegDesk helps manufacturers centralize regulatory information, streamline submissions, and maintain compliance across global markets.

BOOK A DEMO

Frequently Asked Questions

What is medical device regulatory compliance?
How do EU MDR and IVDR differ from previous regulations?
What is CE Marking?
What is EUDAMED?
What is ISO 13485?
What documents are required for EU MDR compliance?
What is a Technical File?
What is PMCF?
What is GSPR?
How long does medical device regulatory approval take?
What is the role of a notified body under EU MDR?
How do RIM and PLM systems support compliance?

What is medical device regulatory compliance?

Medical device regulatory compliance is the process of ensuring that medical devices meet all applicable safety, quality, performance, and regulatory requirements throughout the product lifecycle. Compliance activities include technical documentation management, clinical evidence generation, quality system maintenance, regulatory submissions, post-market surveillance, and vigilance reporting across global markets.

How do EU MDR and IVDR differ from previous regulations?

EU MDR and IVDR introduced significantly stricter requirements compared to MDD and IVDD. Key changes include expanded clinical evidence expectations, increased notified body oversight, stronger post-market surveillance requirements, enhanced UDI traceability, and more detailed technical documentation obligations. Many devices previously self-certified under IVDD now require notified body review under IVDR.

What is CE Marking?

CE Marking is the declaration that a medical device meets applicable EU legislation, including EU MDR or IVDR. It grants market access across EU member states and certain other countries. For most medical devices, CE Marking requires a conformity assessment by a designated notified body, along with a Declaration of Conformity and maintained technical documentation.

What is EUDAMED?

EUDAMED (European Database on Medical Devices) is the EU’s centralized platform for managing regulatory information related to medical devices and IVDs,  including economic operators, device registrations, certificates, clinical investigations, vigilance, and market surveillance. As of May 28, 2026, four modules are mandatory; remaining modules are still under development.

What is ISO 13485?

ISO 13485 is an internationally recognized standard specifying requirements for a quality management system specific to the medical device industry. It provides a framework for organizations involved in the design, production, installation, and servicing of medical devices. Compliance is often a prerequisite for regulatory submissions and is referenced by global regulatory authorities.

What documents are required for EU MDR compliance?

EU MDR compliance requires comprehensive technical documentation demonstrating device safety, performance, and regulatory conformity. Common documentation includes technical files, Clinical Evaluation Reports (CERs), risk management files, verification and validation records, labeling and IFU, post-market surveillance documentation, vigilance records, and UDI traceability information.

What is a Technical File?

A Technical File is the compilation of documents required under EU MDR Annex II demonstrating that a device meets all applicable requirements. It includes device descriptions and specifications, design and manufacturing information, GSPR evidence, benefit-risk analyses, verification and validation records, labeling, and UDI information. The file must be kept current and available to authorities upon request.

What is PMCF?

PMCF (Post-Market Clinical Follow-Up) is a continuous process of proactively collecting and evaluating clinical data from post-market experience to confirm the ongoing safety, performance, and benefit-risk profile of a device. Under EU MDR, PMCF is a required component of the PMS system for most device classes and may include registries, surveys, follow-up studies, and systematic literature reviews.

What is GSPR?

GSPR (General Safety and Performance Requirements) are the fundamental requirements a medical device must meet to receive CE Marking under EU MDR, defined in Annex I. The GSPR checklist covers safety requirements, design and construction requirements, information supplied with the device, and specific requirements for different device types. Manufacturers must document conformity with each applicable GSPR.

How long does medical device regulatory approval take?

Approval timelines vary depending on the region, device classification, submission pathway, and submission quality. Lower-risk devices may receive approval within several months, while higher-risk products can take multiple years. Under EU MDR and IVDR, limited notified body capacity and expanded documentation requirements have contributed to longer review timelines.

What is the role of a notified body under EU MDR?

A notified body is an independent organization designated by European authorities to assess whether medical devices comply with EU MDR requirements. Notified bodies conduct conformity assessments, review technical documentation, audit quality management systems, and evaluate clinical evidence for higher-risk devices. Successful notified body review is required before manufacturers can obtain CE Marking for most medical devices.

How do RIM and PLM systems support compliance?

RIM and PLM systems help manufacturers centralize regulatory data, maintain controlled documentation, and improve traceability across the product lifecycle. These platforms support submission management, engineering change control, document version management, audit readiness, and global regulatory coordination. Integrated systems help reduce manual errors, improve workflow visibility, and support more efficient compliance operations.